Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jun 2;2019:5952836. doi: 10.1155/2019/5952836

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 Zhixian Liu et al.

This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

TP53-mutated breast cancers (BCs) more highly express immune checkpoint genes and have a worse 20-year survival than TP53-wildtype BCs and associated with unfavorable survival prognosis in BC, while higher degree of immune cell infiltration is associated with a 20-year better survival prognosis in BC. (a) A number of important immune checkpoint genes are upregulated in TP53-mutated BCs versus TP53-wildtype BCs. (b) Kaplan-Meier survival curves show that TP53-mutated BCs have a worse 20-year survival prognosis than TP53-wildtype BCs. (c) Kaplan-Meier survival curves show that higher degree of immune cell infiltration is associated with a better 20-year survival prognosis in TP53-mutated BCs. The log-rank test P<0.05 indicates the significance of survival-time differences between two classes of patients.